A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline or Somatic BRCA1/2 Mutations.
Phase: PHASE3
Conditions: HER2-ve Metastatic Breast Cancer, Germline BRCA1/2 Mutations, Somatic BRCA1/2 Mutations
Sponsor: AstraZeneca

L U C Y - L y n p arz a Bre ast C a ncer Re al- W orl d Utilit y, 
Cli nic al Effecti ve ness a n d S afet y St u d y
A P h ase III b, Si n gle- ar m, O pe n-l a bel M ultice ntre St u d y of 
Ol a p ari b M o n ot her a p y i n t he Tre at me nt of H E R 2- ve 
Met ast atic Bre ast C a ncer P atie nts wit h Ger mli ne or S o m atic 
B R C A 1/ 2 M ut ati o ns
Cli nic al Tri als. g o v I de ntifier: N C T 0 3 2 8 6 8 4 2
    Ori gi n al Pr ot oc ol: 1 4 J ul 2 0 1 7  ( Versi o n 1. 0)  
A me n d me nt 1: 2 7 A pr 2 0 1 8  ( Versi o n 2. 0)  
A me n d me nt 2: 2 2 Oct  2 0 2 0 ( Versi o n 3. 0)  
A me n d me nt 3: 1 9 A pr 2 0 2 1  ( Versi o n 4. 0)

C CI
C CI
C CI
C CI

C CI
C CI
C CI
C CI
C CI
C CI

C CI
C CI
C CI
C CI
C CI
C CI

C CI
C CI
C CI
C CI

C CI

C CI

C CI
C CI

C CI

P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D











ø ¼ ¼ó Ó Ó Óó § § § § Ø Øæ ³ ³  Ë Ì Ý Æ÷





 


P P D
P P D
P P D
C CI